Anuria following phenylbutazone therapy.

IN recent years there has been an increased use of phenylbutazone (3,5-dioxo-1,2-diphenyl-4-n-butyl pyrazolidine) as a general antiarthritic. Because of possibly indiscriminate administration and subsequent harmful effects, it is considered timely to review some of the more important toxic side reactions, and to include a case report of an undesirable sequela. In a review of the literature, many complications and toxic reactions have been listed, including the following: granulocytopenia; thrombocytopenia; temporary and mild secondary anemia; hepatotoxicity and jaundice; Stevens-Johnson syndrome and other cutaneous manifestations; sensitivity reactions resembling polyarteritis nodosa; reactivation of peptic ulcer, with perforation and hemorrhage; retention of water, sodium . . .